Comparative Pharmacology
Head-to-head clinical analysis: AZELASTINE HYDROCHLORIDE versus LEVOCETIRIZINE HYDROCHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AZELASTINE HYDROCHLORIDE versus LEVOCETIRIZINE HYDROCHLORIDE.
AZELASTINE HYDROCHLORIDE vs LEVOCETIRIZINE HYDROCHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Azelastine hydrochloride is a phthalazinone derivative that exerts its effect by competitively inhibiting histamine at the H1 receptor site. It also stabilizes mast cells, reducing the release of inflammatory mediators such as histamine, leukotrienes, and cytokines. This dual action provides both antihistaminic and anti-inflammatory effects.
Levocetirizine is a selective peripheral histamine H1-receptor antagonist. It inhibits the effects of histamine at the H1 receptor, reducing allergic symptoms such as itching, sneezing, and rhinorrhea. It has lower affinity for central H1 receptors and anticholinergic properties compared to first-generation antihistamines.
1 spray (137 mcg) per nostril twice daily; ophthalmic: 1 drop in affected eye(s) twice daily.
Oral, 5 mg once daily in the evening.
None Documented
None Documented
Terminal elimination half-life is approximately 22 hours (range 20–25 hours) following oral administration, supporting twice-daily dosing. For ophthalmic and intranasal routes, systemic half-life is similar due to absorption.
Terminal elimination half-life: 7–8 hours in healthy adults; prolonged to 20–24 hours in renal impairment (CrCl <40 mL/min); clinically, stable levels require 2–3 days.
Approximately 75% of the dose is excreted in feces as unchanged drug and metabolites; about 25% is excreted renally, with less than 10% as unchanged drug.
Approximately 85% renal excretion as unchanged drug via glomerular filtration and tubular secretion, 12.9% fecal excretion, <1% biliary.
Category C
Category A/B
Antihistamine
Antihistamine